Q-omics provides the consensus-scored CT66 profile across patient tissues and cancer cell-line models. CT66 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CT66 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, CT66 RNA expression shows 16,977 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, THCA, and UVM as cancer lineages where CT66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT66 survival associations across molecular data types. CT66 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT66 RNA expression–survival associations across cancer types. High CT66 expression shows unfavorable associations in UCEC and KIRC, but favorable associations in PAAD, UCS, LAML and LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CT66 RNA expression.
This table summarizes CT66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CT66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT66 shows lower tumor expression in THCA, BRCA, UCEC and STAD and higher tumor expression in LIHC and KIRP. The THCA box plot shows higher CT66 RNA expression in normal versus tumor tissue (log2 FC = −0.595, t-test p < 0.001).
This table shows molecular features associated with CT66 in patient tissues and cancer cell lines. In patient samples, CT66 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
